vs

Side-by-side financial comparison of BICYCLE THERAPEUTICS PLC (BCYC) and PETMED EXPRESS INC (PETS). Click either name above to swap in a different company.

BICYCLE THERAPEUTICS PLC is the larger business by last-quarter revenue ($48.0M vs $40.7M, roughly 1.2× PETMED EXPRESS INC). PETMED EXPRESS INC runs the higher net margin — -26.0% vs -42.0%, a 16.1% gap on every dollar of revenue. On growth, BICYCLE THERAPEUTICS PLC posted the faster year-over-year revenue change (1193.3% vs -23.3%). PETMED EXPRESS INC produced more free cash flow last quarter ($-9.2M vs $-19.9M). Over the past eight quarters, BICYCLE THERAPEUTICS PLC's revenue compounded faster (56.7% CAGR vs -20.9%).

Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical firm developing innovative bicyclic peptide therapies for unmet medical needs. Its core pipeline covers oncology, rare diseases, and immunological disorders, with operations in Europe and North America, and partnerships with global pharma leaders to advance drug candidates to market.

PetMed Express, Inc., also known as PetMeds, is an online pet pharmacy based in the United States. It is publicly traded and sells prescription and non-prescription pet medication.

BCYC vs PETS — Head-to-Head

Bigger by revenue
BCYC
BCYC
1.2× larger
BCYC
$48.0M
$40.7M
PETS
Growing faster (revenue YoY)
BCYC
BCYC
+1216.5% gap
BCYC
1193.3%
-23.3%
PETS
Higher net margin
PETS
PETS
16.1% more per $
PETS
-26.0%
-42.0%
BCYC
More free cash flow
PETS
PETS
$10.7M more FCF
PETS
$-9.2M
$-19.9M
BCYC
Faster 2-yr revenue CAGR
BCYC
BCYC
Annualised
BCYC
56.7%
-20.9%
PETS

Income Statement — Q4 FY2025 vs Q3 FY2026

Metric
BCYC
BCYC
PETS
PETS
Revenue
$48.0M
$40.7M
Net Profit
$-20.2M
$-10.6M
Gross Margin
23.3%
Operating Margin
-51.5%
-25.7%
Net Margin
-42.0%
-26.0%
Revenue YoY
1193.3%
-23.3%
Net Profit YoY
61.1%
-1392.6%
EPS (diluted)
$-0.29
$-0.50

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
BCYC
BCYC
PETS
PETS
Q4 25
$48.0M
$40.7M
Q3 25
$11.7M
$44.4M
Q2 25
$2.9M
$51.2M
Q1 25
$10.0M
$50.8M
Q4 24
$3.7M
$52.0M
Q3 24
$2.7M
$58.0M
Q2 24
$9.4M
$66.2M
Q1 24
$19.5M
$65.1M
Net Profit
BCYC
BCYC
PETS
PETS
Q4 25
$-20.2M
$-10.6M
Q3 25
$-59.1M
$-8.5M
Q2 25
$-79.0M
$-34.2M
Q1 25
$-60.8M
$-11.6M
Q4 24
$-707.0K
Q3 24
$-50.8M
$2.3M
Q2 24
$-39.8M
$3.8M
Q1 24
$-26.6M
$-5.0M
Gross Margin
BCYC
BCYC
PETS
PETS
Q4 25
23.3%
Q3 25
28.0%
Q2 25
28.1%
Q1 25
29.9%
Q4 24
31.0%
Q3 24
32.3%
Q2 24
28.8%
Q1 24
29.3%
Operating Margin
BCYC
BCYC
PETS
PETS
Q4 25
-51.5%
-25.7%
Q3 25
-558.6%
-18.9%
Q2 25
-2965.8%
-66.7%
Q1 25
-703.7%
-11.9%
Q4 24
-0.9%
Q3 24
-2385.9%
1.0%
Q2 24
-498.3%
6.6%
Q1 24
-162.4%
-5.9%
Net Margin
BCYC
BCYC
PETS
PETS
Q4 25
-42.0%
-26.0%
Q3 25
-503.7%
-19.2%
Q2 25
-2703.8%
-66.7%
Q1 25
-608.9%
-22.9%
Q4 24
-1.4%
Q3 24
-1898.4%
4.0%
Q2 24
-425.3%
5.7%
Q1 24
-136.0%
-7.7%
EPS (diluted)
BCYC
BCYC
PETS
PETS
Q4 25
$-0.29
$-0.50
Q3 25
$-0.85
$-0.41
Q2 25
$-1.14
$-1.65
Q1 25
$-0.88
$-0.56
Q4 24
$-0.03
Q3 24
$-0.74
$0.11
Q2 24
$-0.77
$0.18
Q1 24
$-0.62
$-0.24

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
BCYC
BCYC
PETS
PETS
Cash + ST InvestmentsLiquidity on hand
$628.1M
$26.9M
Total DebtLower is stronger
Stockholders' EquityBook value
$610.0M
$32.8M
Total Assets
$717.6M
$88.0M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
BCYC
BCYC
PETS
PETS
Q4 25
$628.1M
$26.9M
Q3 25
$648.3M
$36.1M
Q2 25
$721.5M
$41.1M
Q1 25
$793.0M
$54.7M
Q4 24
$879.5M
$50.1M
Q3 24
$890.9M
$52.0M
Q2 24
$961.4M
$46.0M
Q1 24
$457.0M
$55.3M
Total Debt
BCYC
BCYC
PETS
PETS
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
$30.9M
Q1 24
$30.8M
Stockholders' Equity
BCYC
BCYC
PETS
PETS
Q4 25
$610.0M
$32.8M
Q3 25
$618.5M
$43.1M
Q2 25
$668.9M
$51.5M
Q1 25
$740.3M
$85.1M
Q4 24
$793.1M
$96.2M
Q3 24
$831.0M
$96.4M
Q2 24
$873.8M
$93.5M
Q1 24
$356.0M
$96.7M
Total Assets
BCYC
BCYC
PETS
PETS
Q4 25
$717.6M
$88.0M
Q3 25
$764.0M
$100.3M
Q2 25
$832.2M
$109.8M
Q1 25
$883.9M
$148.7M
Q4 24
$956.9M
$144.8M
Q3 24
$996.7M
$146.0M
Q2 24
$1.1B
$152.7M
Q1 24
$547.1M
$169.9M
Debt / Equity
BCYC
BCYC
PETS
PETS
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
0.04×
Q1 24
0.09×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
BCYC
BCYC
PETS
PETS
Operating Cash FlowLast quarter
$-19.3M
$-9.2M
Free Cash FlowOCF − Capex
$-19.9M
$-9.2M
FCF MarginFCF / Revenue
-41.5%
-22.7%
Capex IntensityCapex / Revenue
1.2%
0.1%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-252.0M
$-23.0M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
BCYC
BCYC
PETS
PETS
Q4 25
$-19.3M
$-9.2M
Q3 25
$-71.2M
$-2.2M
Q2 25
$-72.8M
$-12.3M
Q1 25
$-86.4M
$7.0M
Q4 24
$-164.7M
$-1.2M
Q3 24
$-39.8M
$7.4M
Q2 24
$-44.6M
$-8.5M
Q1 24
$-70.9M
$7.1M
Free Cash Flow
BCYC
BCYC
PETS
PETS
Q4 25
$-19.9M
$-9.2M
Q3 25
$-71.8M
$-4.8M
Q2 25
$-73.3M
$-13.6M
Q1 25
$-87.0M
$4.6M
Q4 24
$-166.0M
$-1.9M
Q3 24
$-40.3M
$6.1M
Q2 24
$-45.0M
$-9.2M
Q1 24
$-70.9M
$5.9M
FCF Margin
BCYC
BCYC
PETS
PETS
Q4 25
-41.5%
-22.7%
Q3 25
-612.3%
-10.8%
Q2 25
-2509.7%
-26.5%
Q1 25
-871.7%
9.1%
Q4 24
-4475.7%
-3.7%
Q3 24
-1504.7%
10.6%
Q2 24
-481.2%
-13.9%
Q1 24
-362.9%
9.0%
Capex Intensity
BCYC
BCYC
PETS
PETS
Q4 25
1.2%
0.1%
Q3 25
5.7%
5.9%
Q2 25
17.1%
2.5%
Q1 25
6.1%
4.7%
Q4 24
33.3%
1.5%
Q3 24
16.3%
2.2%
Q2 24
4.5%
1.0%
Q1 24
0.1%
1.9%
Cash Conversion
BCYC
BCYC
PETS
PETS
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
3.18×
Q2 24
-2.27×
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

BCYC
BCYC

Segment breakdown not available.

PETS
PETS

Reorder$34.0M84%
New Order$5.0M12%
Membership Fees$1.6M4%

Related Comparisons